PPARA and metabolic dysfunction-associated steatotic liver disease: Fenofibrates, a class of PPARα agonists, were also shown to improve hepatic steatosis in a mouse model of hereditary fatty liver in absence of obesity or diabetes [45] and in OLETF rats, which spontaneously develop NAFLD [32].